tiprankstipranks
Immunocore Holdings Prepares Early Loan Agreement Termination
Company Announcements

Immunocore Holdings Prepares Early Loan Agreement Termination

Don't Miss Our Christmas Offers:

Immunocore Holdings ( (IMCR) ) has shared an announcement.

Immunocore Limited has fully prepaid its $52 million Pharmakon Loan Agreement, originally set to mature in 2028, effectively terminating all related obligations. This strategic financial move included a principal repayment of $50 million, along with $0.5 million in accrued interest and $1.5 million in prepayment and other fees, demonstrating a proactive approach to managing debt and potentially strengthening their financial position.

For an in-depth examination of IMCR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmunocore announces first patient dosed in Phase 1 trial of IMC-P115C
TheFlyImmunocore announces treatment of first patient in Phase 1/2 trial of IMC-R117C
TheFlyImmunocore downgraded to Equal Weight from Overweight at Morgan Stanley
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App